Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Open-label, Single-arm, Multicentre Phase 3 Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases

NCT04640142 is registered in ClinicalTrials.gov with Octapharma as lead sponsor.

NCT NCT04640142
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04640142 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Open-label, Single-arm, Multicentre Phase 3 Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases
Lead sponsor
Octapharma
Phase
Phase 3
Overall status
Active, not recruiting
Start date
August 4, 2021
Completion date
September 30, 2026
Enrollment
50 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

primary immune deficiency